Promega, alongside several research institutions, announced recently the publication of a new study in Nature Communications, highlighting technological advances that may accelerate breakthroughs in precision medicine.

According to a release, the work leverages Promega’s bioluminescent NanoBRET Target Engagement (TE) technology to characterize inhibitors that selectively target cancer cells without harming noncancerous cells. It is the first to characterize uncompetitive binding directly in live cells, illuminating a mechanistic bridge between cancer metabolism and precision oncology.

“This work underscores the value of research collaborations between academia and industry,” Promega Associate Director of R&D and Co-Senior Author of the Study Matt Robers said in a statement. “By combining our complementary expertise in chemical biology and assay design, we were able to dissect how cooperativity can drive cancer cell selectivity. These findings have real potential to guide the development of future precision medicines.”

Promega conducted the study with the Center for Advanced Study of Drug Action at the State University of New York at Stony Brook and the Centre for Medicines Discovery at the University of Oxford, with additional contributions from researchers at Boston University and the Structural Genomics Consortium at the University of Toronto.